Susquehanna International Group, LLP Actinium Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 07, 2024	BUY	$5.0 - $9.2 $102,000 - $187,680	20,400 Added 60.9%	53,900 $422,000
Q4 2023 Feb 14, 2024	BUY	$4.02 - $6.08 $12,059 - $18,240	3,000 Added 9.84%	33,500 $170,000
Q3 2023 Nov 14, 2023	SELL	$5.91 - $7.37 $211,578 - $263,846	-35,800 Reduced 54.0%	30,500 $180,000
Q2 2023 Aug 11, 2023	SELL	$7.15 - $9.39 $8,580 - $11,268	-1,200 Reduced 1.78%	66,300 $491,000
Q1 2023 May 16, 2023	BUY	$8.51 - $14.26 $221,260 - $370,760	26,000 Added 62.65%	67,500 $637,000

Q4 2022 Feb 14, 2023	BUY	$9.71 - $12.51 $155,360 - $200,160	16,000 Added 62.75%	41,500 $441,000
Q3 2022 Nov 14, 2022	SELL	$4.81 - $8.48 $334,776 - $590,208	-69,600 Reduced 73.19%	25,500 $188,000

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.